Cargando…

Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life

INTRODUCTION AND BACKGROUND: Choosing the right treatment for the right patient in a setting of metastatic cancer disease remains a challenge. To facilitate clinical decision-making, predictive tools have been developed to personalize treatment. Here, we aim to assess the use of the recently propose...

Descripción completa

Detalles Bibliográficos
Autores principales: Christ, Sebastian M., Schettle, Markus, Willmann, Jonas, Ahmadsei, Maiwand, Seiler, Annina, Blum, David, Guckenberger, Matthias, Andratschke, Nicolaus, Hertler, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038557/
https://www.ncbi.nlm.nih.gov/pubmed/35496816
http://dx.doi.org/10.1016/j.ctro.2022.04.005
_version_ 1784693949431021568
author Christ, Sebastian M.
Schettle, Markus
Willmann, Jonas
Ahmadsei, Maiwand
Seiler, Annina
Blum, David
Guckenberger, Matthias
Andratschke, Nicolaus
Hertler, Caroline
author_facet Christ, Sebastian M.
Schettle, Markus
Willmann, Jonas
Ahmadsei, Maiwand
Seiler, Annina
Blum, David
Guckenberger, Matthias
Andratschke, Nicolaus
Hertler, Caroline
author_sort Christ, Sebastian M.
collection PubMed
description INTRODUCTION AND BACKGROUND: Choosing the right treatment for the right patient in a setting of metastatic cancer disease remains a challenge. To facilitate clinical decision-making, predictive tools have been developed to personalize treatment. Here, we aim to assess the use of the recently proposed “METSSS score” as a prognostic tool for overall survival of cancer patients after palliative radiotherapy in the last phase of life. METHODS: All patients treated with palliative radiotherapy at the end-of-life at the Department of Radiation Oncology of the University Hospital Zurich between January 2010 and December 2019 were included in this study. Data on demographics, diagnosis, treatment and comorbidities was extracted from the treatment planning and the electronical medical records system. To statistically assess the validity of the “METSSS score”, the mortality risk score was calculated, followed by stratification of all patients to prognostic risk groups. The prediction of the 1-year overall survival estimates was subsequently calculated. RESULTS: Over the past decade, 274 patients have received palliative radiotherapy during the end-of-life period. One third of patients was female (34%, n = 93). The most frequent primary tumor was lung cancer (n = 121, 44%), and 55% of patients (n = 152) had no comorbidities according to the Charlson-Deyo comorbidity index. The most common radiotherapy site was the brain and eye region (42%, n = 115). The median actual overall survival of all patients was 40 days from the start of radiotherapy. The “METSSS score” survival model predicted that 269 patients (98.1%) belong into the high-risk, four patients (1.5%) into the medium-risk, and one patient (0.4%) into the low-risk group. The predicted median 1-year overall survival was 10%. DISCUSSION: The METSSS score correctly predicted the survival of our end-of-life patient cohort by assigning them into the highest risk category, and it can therefore serve as a decision-making tool when assigning patient to symptomatic radiotherapy.
format Online
Article
Text
id pubmed-9038557
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90385572022-04-27 Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life Christ, Sebastian M. Schettle, Markus Willmann, Jonas Ahmadsei, Maiwand Seiler, Annina Blum, David Guckenberger, Matthias Andratschke, Nicolaus Hertler, Caroline Clin Transl Radiat Oncol Original Research Article INTRODUCTION AND BACKGROUND: Choosing the right treatment for the right patient in a setting of metastatic cancer disease remains a challenge. To facilitate clinical decision-making, predictive tools have been developed to personalize treatment. Here, we aim to assess the use of the recently proposed “METSSS score” as a prognostic tool for overall survival of cancer patients after palliative radiotherapy in the last phase of life. METHODS: All patients treated with palliative radiotherapy at the end-of-life at the Department of Radiation Oncology of the University Hospital Zurich between January 2010 and December 2019 were included in this study. Data on demographics, diagnosis, treatment and comorbidities was extracted from the treatment planning and the electronical medical records system. To statistically assess the validity of the “METSSS score”, the mortality risk score was calculated, followed by stratification of all patients to prognostic risk groups. The prediction of the 1-year overall survival estimates was subsequently calculated. RESULTS: Over the past decade, 274 patients have received palliative radiotherapy during the end-of-life period. One third of patients was female (34%, n = 93). The most frequent primary tumor was lung cancer (n = 121, 44%), and 55% of patients (n = 152) had no comorbidities according to the Charlson-Deyo comorbidity index. The most common radiotherapy site was the brain and eye region (42%, n = 115). The median actual overall survival of all patients was 40 days from the start of radiotherapy. The “METSSS score” survival model predicted that 269 patients (98.1%) belong into the high-risk, four patients (1.5%) into the medium-risk, and one patient (0.4%) into the low-risk group. The predicted median 1-year overall survival was 10%. DISCUSSION: The METSSS score correctly predicted the survival of our end-of-life patient cohort by assigning them into the highest risk category, and it can therefore serve as a decision-making tool when assigning patient to symptomatic radiotherapy. Elsevier 2022-04-12 /pmc/articles/PMC9038557/ /pubmed/35496816 http://dx.doi.org/10.1016/j.ctro.2022.04.005 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Christ, Sebastian M.
Schettle, Markus
Willmann, Jonas
Ahmadsei, Maiwand
Seiler, Annina
Blum, David
Guckenberger, Matthias
Andratschke, Nicolaus
Hertler, Caroline
Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
title Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
title_full Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
title_fullStr Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
title_full_unstemmed Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
title_short Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
title_sort validation and extension of the metsss score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038557/
https://www.ncbi.nlm.nih.gov/pubmed/35496816
http://dx.doi.org/10.1016/j.ctro.2022.04.005
work_keys_str_mv AT christsebastianm validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT schettlemarkus validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT willmannjonas validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT ahmadseimaiwand validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT seilerannina validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT blumdavid validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT guckenbergermatthias validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT andratschkenicolaus validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife
AT hertlercaroline validationandextensionofthemetsssscoreinametastaticcancerpatientcohortafterpalliativeradiotherapywithinthelastphaseoflife